121 related articles for article (PubMed ID: 28434815)
1. Is Canada Ready to Adopt Maternal Placental Growth Factor Testing to Improve Clinical Outcomes for Women with Suspected Preeclampsia?
Walker MG; Bujold E; Kingdom JC
J Obstet Gynaecol Can; 2017 Jul; 39(7):580-583. PubMed ID: 28434815
[No Abstract] [Full Text] [Related]
2. Diagnostic Performance of Placental Growth Factor in Women With Suspected Preeclampsia Attending Antenatal Facilities in Maputo, Mozambique.
Ukah UV; Mbofana F; Rocha BM; Loquiha O; Mudenyanga C; Usta M; Urso M; Drebit S; Magee LA; von Dadelszen P
Hypertension; 2017 Mar; 69(3):469-474. PubMed ID: 28137987
[TBL] [Abstract][Full Text] [Related]
3. Early diagnosis of preeclampsia using placental growth factor: An operational pilot study in Maputo, Mozambique.
Manriquez Rocha B; Mbofana F; Loquiha O; Mudenyanga C; Ukah UV; Magee LA; von Dadelszen P
Pregnancy Hypertens; 2018 Jan; 11():26-31. PubMed ID: 29523269
[TBL] [Abstract][Full Text] [Related]
4. KRYPTOR-automated angiogenic factor assays and risk of preeclampsia-related adverse outcomes.
Salahuddin S; Wenger JB; Zhang D; Thadhani R; Karumanchi SA; Rana S
Hypertens Pregnancy; 2016 Aug; 35(3):330-45. PubMed ID: 27028795
[TBL] [Abstract][Full Text] [Related]
5. Prediction of preeclampsia in primigravida in late first trimester using serum placental growth factor alone and by combination model.
Agarwal R; Chaudhary S; Kar R; Radhakrishnan G; Tandon A
J Obstet Gynaecol; 2017 Oct; 37(7):877-882. PubMed ID: 28569565
[TBL] [Abstract][Full Text] [Related]
6. First-trimester screening for early and late preeclampsia using maternal characteristics, biomarkers, and estimated placental volume.
Sonek J; Krantz D; Carmichael J; Downing C; Jessup K; Haidar Z; Ho S; Hallahan T; Kliman HJ; McKenna D
Am J Obstet Gynecol; 2018 Jan; 218(1):126.e1-126.e13. PubMed ID: 29097177
[TBL] [Abstract][Full Text] [Related]
7. [Is universal first trimester screening for high risk of preterm preeclampsia clinically meaningful?].
Sentilhes L; Azria E; Schmitz T
Gynecol Obstet Fertil Senol; 2018 Sep; 46(9):617-618. PubMed ID: 29656070
[No Abstract] [Full Text] [Related]
8. Placental growth factor (PlGF) and sFlt-1 during pregnancy: physiology, assay and interest in preeclampsia.
Lecarpentier É; Vieillefosse S; Haddad B; Fournier T; Leguy MC; Guibourdenche J; Tsatsaris V
Ann Biol Clin (Paris); 2016 Jun; 74(3):259-67. PubMed ID: 27237799
[TBL] [Abstract][Full Text] [Related]
9. In vivo uteroplacental release of placental growth factor and soluble Fms-like tyrosine kinase-1 in normal and preeclamptic pregnancies.
Holme AM; Roland MC; Henriksen T; Michelsen TM
Am J Obstet Gynecol; 2016 Dec; 215(6):782.e1-782.e9. PubMed ID: 27503620
[TBL] [Abstract][Full Text] [Related]
10. ASPRE trial: performance of screening for preterm pre-eclampsia.
Rolnik DL; Wright D; Poon LCY; Syngelaki A; O'Gorman N; de Paco Matallana C; Akolekar R; Cicero S; Janga D; Singh M; Molina FS; Persico N; Jani JC; Plasencia W; Papaioannou G; Tenenbaum-Gavish K; Nicolaides KH
Ultrasound Obstet Gynecol; 2017 Oct; 50(4):492-495. PubMed ID: 28741785
[TBL] [Abstract][Full Text] [Related]
11. The Use of Soluble FMS-like Tyrosine Kinase 1/Placental Growth Factor Ratio in the Clinical Management of Pre-eclampsia.
Govender N; Moodley J; Naicker T
Afr J Reprod Health; 2018 Dec; 22(4):135-143. PubMed ID: 30632730
[TBL] [Abstract][Full Text] [Related]
12. Association of first-trimester angiogenic factors with placental histological findings in late-onset preeclampsia.
Triunfo S; Crovetto F; Crispi F; Rodriguez-Sureda V; Dominguez C; Nadal A; Peguero A; Gratacos E; Figueras F
Placenta; 2016 Jun; 42():44-50. PubMed ID: 27238713
[TBL] [Abstract][Full Text] [Related]
13. Importance of Timing First-Trimester Placental Growth Factor and Use of Serial First-Trimester Placental Growth Factor Measurements in Screening for Preeclampsia.
Mosimann B; Amylidi-Mohr S; Höland K; Surbek D; Risch L; Raio L
Fetal Diagn Ther; 2017; 42(2):111-116. PubMed ID: 28199996
[TBL] [Abstract][Full Text] [Related]
14. Study protocol for the randomised controlled trial: combined multimarker screening and randomised patient treatment with ASpirin for evidence-based PREeclampsia prevention (ASPRE).
O'Gorman N; Wright D; Rolnik DL; Nicolaides KH; Poon LC
BMJ Open; 2016 Jun; 6(6):e011801. PubMed ID: 27354081
[TBL] [Abstract][Full Text] [Related]
15. [Application of the concetrations ratio of soluble receptor tyrosine kinase type 1, and placental growth factor for short-term prediction and diagnosis of preeclampsia].
Bubeníková Š; Cíchová A; Roubalová L; Durdová V; Vlk R
Ceska Gynekol; 2016; 81(4):272-278. PubMed ID: 27882748
[TBL] [Abstract][Full Text] [Related]
16. Competing risks model in screening for preeclampsia by maternal factors and biomarkers at 19-24 weeks' gestation.
Gallo DM; Wright D; Casanova C; Campanero M; Nicolaides KH
Am J Obstet Gynecol; 2016 May; 214(5):619.e1-619.e17. PubMed ID: 26627730
[TBL] [Abstract][Full Text] [Related]
17. Screening for preeclampsia using first-trimester serum markers and uterine artery Doppler in nulliparous women.
Audibert F; Boucoiran I; An N; Aleksandrov N; Delvin E; Bujold E; Rey E
Am J Obstet Gynecol; 2010 Oct; 203(4):383.e1-8. PubMed ID: 20691410
[TBL] [Abstract][Full Text] [Related]
18. Placental growth factor (alone or in combination with soluble fms-like tyrosine kinase 1) as an aid to the assessment of women with suspected pre-eclampsia: systematic review and economic analysis.
Frampton GK; Jones J; Rose M; Payne L
Health Technol Assess; 2016 Nov; 20(87):1-160. PubMed ID: 27918253
[TBL] [Abstract][Full Text] [Related]
19. Economic assessment of the use of the sFlt-1/PlGF ratio test to predict preeclampsia in Germany.
Schlembach D; Hund M; Schroer A; Wolf C
BMC Health Serv Res; 2018 Aug; 18(1):603. PubMed ID: 30081904
[TBL] [Abstract][Full Text] [Related]
20. [Angiogenic factors can be used when pre-eclampsia is suspected].
Andrea MK; Lykke JA
Ugeskr Laeger; 2015 May; 177(22):V11140638. PubMed ID: 26027672
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
